Loading organizations...
§ Private Profile · Cologne, Nordrhein-Westfalen, Germany
Biotechnology company developing LUNARIS™ biochip technology for multiplex protein analysis from small samples in life sciences and clinical research.
Based in Cologne, Germany, AYOXXA is a biotechnology company that develops multiplex protein analysis technologies and proprietary biochips for life sciences and clinical research. The organization's core LUNARIS platform enables the simultaneous measurement of multiple biomarkers from extremely small biological sample volumes, yielding significantly more data than standard assays. Operating with approximately 30 to 50 employees, the enterprise has raised over €30 million in total venture funding to support its research and commercialization efforts. AYOXXA has secured financial backing from prominent institutional investors, including Novartis Venture Fund, Wellington Partners, High-Tech Gründerfonds, and NRW.BANK. Following the commercial launch of its flagship assay platform, the company filed for preliminary insolvency proceedings in late 2022 to initiate corporate restructuring. AYOXXA was founded in 2010 as a spin-off from the National University of Singapore by Andreas Schmidt and Dieter Trau.
AYOXXA has raised $18.3M across 3 funding rounds.
AYOXXA has raised $18.3M in total across 3 funding rounds.
AYOXXA has raised $18.3M across 3 funding rounds. Most recently, it raised $2.8M Series B in December 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2014 | $2.8M Series B | — | BioMedPartners, Grazia Equity | Announced |
| Jul 23, 2014 | $12.1M Series B | — | Btov Partners, High Tech Grunderfonds, HR Ventures, KFW, NRW.BANK, Wellington Partners | Announced |
| Sep 20, 2012 | $3.4M Series A | Lukas Guenther | Rainer Christine, High Tech Grunderfonds, DR. Aristotelis Nastos | Announced |
AYOXXA has raised $18.3M in total across 3 funding rounds.
AYOXXA's investors include BioMedPartners, Grazia Equity, btov Partners, High-Tech Grunderfonds, HR Ventures, KfW, NRW.BANK, Wellington Partners, Lukas Guenther, Rainer Christine, Dr. Aristotelis Nastos.